Eric and Sid talk to John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP). During the interview, John provided an overview of CNS Pharmaceuticals and recent FDA approval to begin clinical trials on the company’s lead drug candidate, Berubicin, a proposed treatment for glioblastoma multiforme (GBM), an incurable brain cancer. The episode is around 20 minutes long and worth a listen! Please note the podcast was recorded on an online platform as a result of social distancing during the COVID-19 Pandemic.
Email questions and comments to [email protected].
Connect on Instagram: https://www.instagram.com/c3chatshowpodcast/
C3 Chat Show Podcast YouTube videos: https://www.youtube.com/playlist?list=PLYx2sBaW2HEWsNE_rNrLJeWcNFICoBPJg
Sid and Eric use Canva to make their image designs. Want to try out Canva: https://canva.7eqqol.net/nws20
Want to learn to podcast and monetize: http://classesbysid.com/
Who is Sid Vaidya and Eric Gershey?
Sid Vaidya: Driven to connect people to help them achieve their dreams and goals. Founder of Switch Events, built to be the platform of the future for professional networking. Sid is a networking expert, best selling author, keynote speaker, and business professional. If you would like to connect with Sid, please contact him on LinkedIn: www.linkedin.com/in/sidvee.
Eric Gershey: CEO and Founder of Jaguar Apps Inc. In addition to serving as CEO and Founder of Jaguar Apps Inc, Eric Gershey is passionate about helping people find their dream job. Their success becomes his motivation to expand this business. He’s created two apps, Nine2Five Job Search app, the all in one job search platform for job seekers, and the Lid app, the Android screen locking application. If you would like to connect with Eric, please contact him on LinkedIn: https://www.linkedin.com/in/eric-gershey-975977148.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.
For more information, visit: www.cnspharma.com
---
Support this podcast: https://anchor.fm/n2fjobsearchpodcast/support
